Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 can cause over 50 long-term symptoms, with fatigue and headache being the most common.

Women with hyperandrogenism have higher androgen levels and lower SHBG, which may contribute to conditions like excessive hair growth and early puberty.

We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.

The enzymes 5α-reductase and 3α/β-hydroxysteroid oxidoreductase help create brain-active substances from progesterone and testosterone, which could be used for treatment, but more research is needed to ensure their safety and effectiveness.

Key enzymes control androgen levels, affecting hormone activity and potential treatments.

Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.

11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.

Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.

Mutants of CYP154C2 enzyme significantly improved steroid conversion efficiency.

Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.

This enzyme helps metabolize fatty acids and isoleucine, and could be key in treating neurological diseases and certain cancers.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Androgen conjugates might be better indicators of skin sensitivity to hormones in women with excessive hair growth.

CYP154C7 enzyme can effectively modify steroids and is promising for commercial use.

Enzymes called 5α-reductases have many body functions and need more research to safely use inhibitors.

Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.

Researchers successfully made new compounds for hormone level tests, but one attempt led to an unexpected product, correcting a past error.

Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.

Human adrenals and gonads have a unique enzyme for steroid hormone production.

The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.

5α-reductases increase epitestosterone's effect on androgen receptors.

Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

The research helps understand how finasteride works and aids drug development.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.

Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Different halogens on progesterone derivatives can either block or mimic male hormone effects, depending on their type and amount.